To investigate the molecular basis of CME and CavME in prostate cancer, we have used a multi-label immunohistochemical technique, combined with unbiased quantitative analysis (Arthurs et al. 2017; Symes et al. 2013), to simultaneously measure the expression of clathrin and caveolin-1, in normal and paired cancerous prostate tissue with different Gleason grades on tissue arrays (TAs). This evidence concerns the gene CAV1 and Familial prostate cancer.